Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK7 | P50613 | 2/20 | 0.40 |
| ▸ | CCNH | P51946 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652254 | 0.88 | KIF11 (0.47) | NR3C2BRD4KIF11MAPTHTT | |
| SCHEMBL18649047 | 0.88 | NR3C2 (0.54) | NR3C2BRD4ADRA2AADRA1AKIF11 | |
| SCHEMBL21652308 | 0.84 | HTT (0.49) | BRD4KIF11MAPTHPGDHTT | |
| SCHEMBL8274370 | 0.84 | NR3C2 (0.57) | NR3C2BRD4ADRA2AADRA1AKIF11 | |
| SCHEMBL20372223 | 0.77 | ALDH1A1 (0.40) | MAPTLMNAHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL16658362 | 0.77 | RORC (0.47) | NR3C2BRD4MAPTSMN1; SMN2LRRK2 | |
| SCHEMBL22928009 | 0.76 | LMNA (0.61) | ADRA2AADRA1ALMNAHTTSMN1; SMN2 | |
| SCHEMBL20366361 | 0.76 | RAB9A (0.54) | MAPTLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL10294172 | 0.76 | NR3C2 (0.50) | NR3C2BRD4ADRA2AADRA1AKIF11 | |
| SCHEMBL18649037 | 0.75 | KIF11 (0.49) | NR3C2BRD4KIF11MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | NR3C2 1906/4885BRD4 5/4885ADRA2A 4642/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | NR3C2 1906/4885BRD4 5/4885ADRA2A 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.